ArcticZymes Technologies — Board/Management Information 2024

May 13, 2024

ArcticZymes Technologies - changes to the Board of Directors

ArcticZymes Technologies - changes to the Board of Directors

Tromsø, Norway, May 13[th], 2024 - ArcticZymes Technologies (OSE: AZT) announces

Nominations for new Board members and the resignation of the Chairman and a

Board member.

ArcticZymes today announces changes to its governance structure. The Election

committee has proposed changes to the Board to guide and strengthen the

strategic and commercial development of the company.

Nomination of New Board Members

ArcticZymes is pleased to introduce three distinguished individuals nominated to

join its Board of directors. These nominees bring expertise and experience in

the biomanufacturing and financial sectors, enriching ArcticZymes' strategic

direction, commercialization efforts, and governance practices:

· Mrs. Sharon Brownlow: With a background in Biotech and extensive experience

in the cell and gene therapy industry, Mrs. Brownlow is renowned for blending

her scientific roots with entrepreneurial drive. Her proven track record

includes senior commercial roles in Catapult and Cobra Biologics, where she

effectively drove strategic business momentum and long-term revenue growth.

· Mr. Petter Dragesund: Former Senior Partner at Pareto Securities, Mr.

Dragesund boasts nearly three decades of experience in investment banking.

Serving in various capacities at Pareto from 1992 to 2021, including Head of the

Corporate Finance department from 2001 to 2014, he brings invaluable financial

acumen to the Board. Since 2021, Mr. Dragesund has been an independent investor,

further broadening his insights into market dynamics.

· A third Board member, currently a Life Science Executive, will be nominated

shortly. With a remarkable track record in scaling public life science companies

and devising successful growth strategies, this individual possesses deep

insights into the challenges and opportunities within drug development and

commercialization broadly.

Resignation of Chairman and Board Member

Mrs. Marie Roskrow, Chairman of the Board, has resigned, effective immediately.

During her six-year tenure, Mrs. Roskrow played a pivotal role in elevating

ArcticZymes into a globally profitable player in the life science tools sector.

Her leadership laid a robust foundation for long-term growth, for which the

Election committee extends its sincere appreciation.

Board member Mrs. Jane Theaker has also resigned, citing personal reasons. The

committee acknowledges Mrs. Theaker's valuable contributions and thanks her for

her service.

New date of the Annual General Meeting (AGM) is June 26[th], 2024

For practical reasons ArcticZymes has decided to move its Annual General Meeting

(AGM), originally scheduled for June 5[th], to June 26[th], 2024. The financial

calendar will be updated as well.

-Ends-

For more information, please contact:

ArcticZymes Technologies ASA

CEO,  MIchael B. Akoh                        Tel: +46 (0) 70 262 37 15

CFO, Børge Sørvoll                              Tel: +47 952 90 187

ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the

development, manufacturing and commercialization of novel recombinant enzymes

for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Listed on the Oslo Stock Exchange since 2005 originally under the [AZT] ticker.

Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large

portfolio of patents.

For more information, please visit the website: www.arcticzymes.com